Daehan Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DaehanPharmaceutical makes intravenous fluids and ampoule-based medicines, the basic liquid drugs that hospitals and clinics use to hydrate and nourish patients who cannot take medication by mouth.
It supplies these products primarily to hospitals and clinics, while also reaching pharmacy consumers through over-the-counter items such as lens-cleaning solutions and sodium chloride wash. Listed on KOSDAQ, Korea's small-cap and technology board, the company derives the large majority of its revenue from the hospital and clinic channel, giving it a concentrated but stable customer base.
Summary is AI-generated and may contain errors · figures from DART filings
Korean pharmaceutical pricing, distribution, and advertising are subject to direct government regulation, which shapes the competitive and margin environment for all domestic drug suppliers.
Daehan Pharmaceutical in five facts
What does Daehan Pharmaceutical do?
DaehanPharmaceutical makes intravenous fluids and ampoule-based medicines, the basic liquid drugs that hospitals and clinics use to hydrate and nourish patients who cannot take medication by mouth.
Where is Daehan Pharmaceutical listed and in which sector?
Daehan Pharmaceutical (Korean name: 대한약품) trades under KRX code 023910 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Daehan Pharmaceutical?
Its market capitalisation was US$115.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Daehan Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Daehan Pharmaceutical reported revenue of US$157.5M, operating profit of US$23.5M and net income of US$20.9M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 2.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 20
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersSep 30
- Report on securities held by executives/major shareholdersAug 31
- Cash/in-kind dividend decision
Daehan Pharmaceutical declared a cash dividend of US$0.69 per share.
Dividend · Feb 11